Prostate cancer has been one of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

February 26, 2007 — A blood test for C-reactive protein (CRP), which is readily available and already used to assess the risk of cardiovascular disease, could be useful in predicting prognosis for men ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

In a new study published in the journal Nature Genetics, Haolong Li, PhD, a researcher at Fred Hutch Cancer Center, and colleagues developed a way to monitor androgen receptor levels inside living ...

Better short-term survival with apalutamide versus darolutamide, but lots of unanswered qu ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

An antidiabetic mainstay did not provide an additional survival benefit to patients with metastatic hormone-sensitive prostate cancer, according to results from a phase III trial. In STAMPEDE, overall ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

Bayer AG (BAYRY) announced an update on their ongoing clinical study.

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

Add Yahoo as a preferred source to see more of our stories on Google. Joe Biden's Cancer Moonshot initiative had funded hundreds of cancer research projects across the country. AP Photo/Gerald Herbert ...